<!DOCTYPE html><html prefix="og: http://ogp.me/ns#" lang="zh">
<!-- Mirrored from cn.nytimes.com/business/20180104/china-drugs-health-care/zh-hant/ by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 28 Jan 2022 14:13:01 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head><meta charset="UTF-8"><!-- Browser render  --><meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"><meta name="renderer" content="webkit"><!-- End Browser render --><meta name="keywords" content=""><meta name="description" content="中國正推動在全球製藥行業發揮更大的作用。多年來以仿製西藥為主的中國藥企開始自主研發治療癌症的新藥，並尋求美國監管部門批准，以打入全球市場。"><meta id="uuid" name="uuid" content="a7202568b3dcdffbe1e0a2cd1896dc06"><meta id="headline" name="headline" content="癌症新藥，中國製造 - 紐約時報中文網"><meta id="byline" name="byline" content="黃瑞黎"><meta id="date" name="date" content="2018-01-04T09:37:45.000Z"><link rel="alternate" href="../index.html" hreflang="zh-Hans"><link rel="alternate" href="index.html" hreflang="zh-Hant"><link rel="alternate" href="https://www.nytimes.com/2018/01/03/business/china-drugs-health-care.html" hreflang="en-us"><link rel="canonical" href="index.html"><link rel="alternate" type="application/rss+xml" href="https://cn.nytimes.com/rss/zh-hant/"><meta name="apple-itunes-app" content="app-id=807498298, app-argument=nytimescn://article:a7202568b3dcdffbe1e0a2cd1896dc06"><meta name="lang" property="lang" content="zh-cmn-hant"><!-- Apple IOS safari private meta --><link rel="apple-touch-icon-precomposed" sizes="144×144" href="../../../../../static01.nyt.com/images/icons/ios-ipad-144x144.png"><link rel="apple-touch-icon-precomposed" sizes="114×114" href="../../../../../static01.nyt.com/images/icons/ios-iphone-114x144.png"><link rel="apple-touch-icon-precomposed" href="../../../../../static01.nyt.com/images/icons/ios-default-homescreen-57x57.png"><meta name="apple-mobile-web-app-title" content="癌症新藥，中國製造 - 紐約時報中文網"><meta name="apple-mobile-web-app-capable" content="yes"><!-- End Apple IOS safari private meta --><!-- Viewport and mobile --><meta name="viewport" content="width=device-width,initial-scale=1,user-scalable=no,maximum-scale=1,minimum-scale=1,minimal-ui"><!-- End viewport and mobile --><meta http-equiv="Cache-Control" content="no-siteapp"><meta name="format-detection" content="telephone=no"><meta name="HandheldFriendly" content="true"><meta name="MobileOptimized" content="320"><meta name="x5-orientation" content="portrait"><meta name="full-screen" content="yes"><meta name="x5-fullscreen" content="true"><meta name="browsermode" content="application"><meta name="x5-page-mode" content="app"><meta name="msapplication-tap-highlight" content="no"><meta property="og:title" content="癌症新藥，中國製造"><meta property="og:type" content="article"><meta property="og:url" content="index.html"><meta property="og:description" content="中國正推動在全球製藥行業發揮更大的作用。多年來以仿製西藥為主的中國藥企開始自主研發治療癌症的新藥，並尋求美國監管部門批准，以打入全球市場。"><meta property="og:site_name" content="紐約時報中文網"><meta property="article:publisher" content="https://www.facebook.com/nytimeschinese"><meta property="article:published_time" content="2018-01-04T09:37:45.000Z"><meta property="fb:pages" content="1504603339831430"><meta property="fb:app_id" content="853699254762608"><meta property="og:image" content="../../../../../static01.nyt.com/images/2018/01/04/business/04CHINAPHARMA5/merlin_131519837_5b70c547-0717-4148-ac1a-e3ac26709e4e-articleLarge.html"><meta property="twitter:card" content="summary_large_image"><meta property="twitter:url" content="index.html"><meta property="twitter:title" content="癌症新藥，中國製造"><meta property="twitter:description" content="中國正推動在全球製藥行業發揮更大的作用。多年來以仿製西藥為主的中國藥企開始自主研發治療癌症的新藥，並尋求美國監管部門批准，以打入全球市場。"><meta property="twitter:domain" content="cn.nytimes.com"><meta property="twitter:site" content="@nytchinese"><meta property="twitter:creator" content="@nytchinese"><meta property="twitter:image:src" content="../../../../../static01.nyt.com/images/2018/01/04/business/04CHINAPHARMA5/merlin_131519837_5b70c547-0717-4148-ac1a-e3ac26709e4e-articleLarge.html"><meta name="PT" content="article"><meta name="PST" content="News"><meta name="CG" content="business"><meta name="SCG" content=""><meta name="sourceApp" content="nyt-china-web"><meta name="ptime" content="20180104070910"><meta name="utime" content="20180104093745"><meta name="pdate" content="20180104"><meta name="dat" content="Jan. 04, 2018"><meta name="hdl" content="癌症新藥，中國製造"><meta name="byl" content="黃瑞黎"><meta name="lp" content="中國正推動在全球製藥行業發揮更大的作用。多年來以仿製西藥為主的中國藥企開始自主研發治療癌症的新藥，並尋求美國監管部門批准，以打入全球市場。"><link rel="shortcut icon" href="https://static01.nyt.com/favicon.ico"><link rel="stylesheet" href="../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/nytcn_core/style-flex.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/web/style.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/nytcn_core/article.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/slideshow/slideshow.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/cookie-banner/style.min619b.css?v=f1810d8"><title>癌症新藥，中國製造 - 紐約時報中文網</title></head><script>var js_static_path = "https://d1f1eryiqyjs0r.cloudfront.net/js";
 var imgs_static_path = "https://d1f1eryiqyjs0r.cloudfront.net/style/imgs";
 var style_static_path = "https://d1f1eryiqyjs0r.cloudfront.net/style";
 var site = 1;
 var sectionName = "business";
 var adTyp = "art";
 var cookieString = {
     "title": "您的追蹤器設置",
     "headline": "我們使用 cookie 做什麼？",
     "summary": '<p>我們利用cookies和類似的技術識別您的重複訪問和偏好。我們還使用它們來衡量廣告系列的效果，定位廣告並分析和網站流量。更多關於cookies的資訊（包括如何停用），<a href="https://www.nytimes.com/zh-hant/privacy/cookie-policy" rel="noreferrer noopener" target="_blank" data-testid="GDPR-policy">請查看我們的「Cookie政策」</a>。</span><span>自2020年7月20日起，我們將根據您在我們服務中所訪問的內容類型向您顯示我們認為與您的興趣相關的廣告。您可以<a href="https://www.nytimes.com/zh-hant/privacy/cookie-policy#how-do-i-manage-trackers" rel="noreferrer noopener" target="_blank" data-testid="GDPR-objection">提出反對</a>。希望了解更多信息，請參見我們的<a href="https://nytimes.com/zh-hant/privacy/privacy-policy#we-allow-for-personalized-advertising-on-times-services" rel="noreferrer noopener" target="_blank" data-testid="GDPR-privacy">隱私政策</a>。</p><p>透過在此處點擊「我接受」或者「X」， 您將被視為同意使用cookies。您隨時可以通過我們的Cookie政策來更改您的跟踪器偏好。</p>',
     "button": "接受",
     "trackerButton": "您的追蹤器設置",
     "rejectButton": "拒絕所有",
     "lang": 'zh-hant',
     "trackerLink": "https://www.nytimes.com/zh-hant/privacy/cookie-policy",
 };
 var purrString = {
     "button": "請勿出售我的個人資訊",
     "snackbar": "你的設定已經保存在此瀏覽器和設備上。如果你清除了 cookie，這些設定也會被清除。",
     "snackbarError": "Something went wrong",
     "optedOutText": "我们不再出售您的個人資訊",
     "CFALinkText": "California Notices",
     "purrPopupTitle": "Your request to not sell your data will be stored for this browser and device",
     "purrPopupSummary": "If you clear your cookies, your preference will be forgotten. As a California resident, you have additional rights under the California Consumer Privacy Act of 2018. While The New York Times Company does not “sell” personal information of its readers as the term “sell” is traditionally understood, “sell” under the CCPA is broadly defined. To learn more, review the text below.",
     "purrPopupButton": "DISMISS",
     "purrPopupScrollContent": 'ssa sed. Nec sagittis aliquam malesuada bibendum arcu. Nunc sed blandit libero volutpat sed cras ornare arcu. Metus vulputate eu scelerisque felis imperdiet proin. Elit eget gravida cum sociis natoque penatibus. Sodales ut eu sem integer. Vitae auctor eu augue ut lectus arcu bibendum at. Vulputate ut pharetra sit amet aliquam id diam. Eu tincidunt tortor aliquam nulla facilisi cras fermentum odio eu. Imperdiet dui accumsan sit amet nulla facilisi morbi. Laoreet non curabitur gravida arcu ac tortor dignissim. Magna fringilla urna porttitor rhoncus dolor purus. In nulla posuere sollicitudin aliquam. At elementum eu facilisis sed odio. Diam in arcu cursus euismod quis viverra. Viverra suspendisse potenti nullam ac tortor vitae purus. Felis donec et odio pellentesque diam volutpat. Lacus sed turpis tincidunt id aliquet risus feugiat in.Aliquam ut porttitor leo a diam sollicitudin tempor',
     "lang": 'zh-hant'
 };
 cbSectionName = "business";
 cbByline = "黃瑞黎";</script><!-- Google Tag Manager --><script>(function(w,d,s,l,i){
     w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});
     var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';
     j.async=true;j.src='../../../../../www.googletagmanager.com/gtm5445.html?id='+i+dl;
     f.parentNode.insertBefore(j,f);
 })(window,document,'script','dataLayer','GTM-KTDZV8V');</script><!-- End Google Tag Manager --><!-- chartbeat --><script type="text/javascript">var _sf_startpt=(new Date()).getTime()</script><!-- /chartbeat --><body class="news"><main class="container-fluid main clearfix"><header class="row title-bar"><div class="nav-button default" id="menuBtn"><i class="icon-bars"></i></div><h1 class="logo"><a href="/"><svg role="img" aria-label="" width="90%" height="90%"><image width="100%" height="100%" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="/d1f1eryiqyjs0r.cloudfront.net/style/imgs/mweb/nytimes-zh-hant.svg" src="../../../../../d1f1eryiqyjs0r.cloudfront.net/style/imgs/mweb/nytimes-zh-hant%402x.png" alt="" border="0"></image></svg></a></h1><div class="nav-button default" id="gearBtn"><i class="icon-gear"></i></div><div class="popup gear-popup"><div class="tips-container"><div class="tips-border"></div><div class="tips-inner"></div></div><div class="popup-container"><div class="popup-body"><div class="setting-title">簡繁中文</div><div class="setting-option"><a href="../index024e.html?changeLang=zh-hans">簡體 </a><a href="../index27d8.html?changeLang=zh-hant" class="active">繁體</a></div><div class="setting-title">紐約時報 出版語言</div><ul class="menu-list"><li><a href="https://www.nytimes.com/">ENGLISH (英語)</a></li><li><a href="https://www.nytimes.com/es/">ESPAÑOL (西班牙語)</a></li></ul><div class="setting-title">字體大小</div><div class="setting-option"><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="small"> 小</label></div><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="normal" checked="checked"> 中</label></div><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="large"> 大</label></div><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="xlarge"> 超大</label></div></div></div></div></div></header><div class="top_banner_ad" id="topad" data-target="{&quot;pos&quot;:&quot;top&quot;,&quot;adv&quot;:&quot;&quot;}"></div><div class="article-area"><div class="setting-bar row"><div class="col-4 section-title"><h3>商業與經濟</h3></div><div class="col-8 setting-btns"><div class="row"><div class="col-6"><ul class="dual-btn"><li><a href="javascript:;" class="active"><span class="setting-btn-text">中文</span> <span class="setting-btn-text-mobile">中</span></a></li><li><a href="dual/index.html"><span class="setting-btn-text">中英雙語</span> <span class="setting-btn-text-mobile">雙語</span></a></li><li><a href="https://www.nytimes.com/2018/01/03/business/china-drugs-health-care.html" target="_blank"><span class="setting-btn-text">英文 <i class="icon-share-square"></i> </span><span class="setting-btn-text-mobile">英</span></a></li></ul></div><div class="col-6 share-tools-top-container"><ul class="share-tools mobile-article"><li><a href="http://v.t.sina.com.cn/share/share.php?&amp;title=%E7%99%8C%E7%97%87%E6%96%B0%E8%97%A5%EF%BC%8C%E4%B8%AD%E5%9C%8B%E8%A3%BD%E9%80%A0&amp;url=https://cn.nytimes.com/business/20180104/china-drugs-health-care/zh-hant/" target="_blank"><i class="icon-weibo"></i></a></li><!-- <li> --><!-- <a href="javascript:void(0);" class="JS_shareForQrcode" data-url="https://cn.nytimes.com/business/20180104/china-drugs-health-care/zh-hant/" data-headline="%E7%99%8C%E7%97%87%E6%96%B0%E8%97%A5%EF%BC%8C%E4%B8%AD%E5%9C%8B%E8%A3%BD%E9%80%A0"> --><!-- <i class="icon-wechat"></i> --><!-- </a> --><!-- </li> --><li><a href="https://www.facebook.com/sharer/sharer.php?u=https://cn.nytimes.com/business/20180104/china-drugs-health-care/zh-hant/" trage="_blank"><i class="icon-facebook"></i></a></li><li><a href="https://plus.google.com/share?url=https://cn.nytimes.com/business/20180104/china-drugs-health-care/zh-hant/" target="_blank"><i class="icon-google"></i></a></li><li><a href="https://twitter.com/share?text=%E7%99%8C%E7%97%87%E6%96%B0%E8%97%A5%EF%BC%8C%E4%B8%AD%E5%9C%8B%E8%A3%BD%E9%80%A0&amp;url=https://cn.nytimes.com/business/20180104/china-drugs-health-care/zh-hant/" target="_blank"><i class="icon-twitter"></i></a></li><li><div class="line-it-button" data-lang="zh_Hant" data-type="share-g" data-url="https://cn.nytimes.com/business/20180104/china-drugs-health-care/zh-hant/" style="display: none;"></div><script src="/d.line-scdn.net/r/web/social-plugin/js/thirdparty/loader.min.js" async="async" defer="defer"></script></li><!-- <li> --><!-- <a href="javascript:void(0);" class="JS_shareForQrcode" data-url="https://cn.nytimes.com/business/20180104/china-drugs-health-care/zh-hant/" data-headline="%E7%99%8C%E7%97%87%E6%96%B0%E8%97%A5%EF%BC%8C%E4%B8%AD%E5%9C%8B%E8%A3%BD%E9%80%A0"> --><!-- <i class="icon-qrcode"></i> --><!-- </a> --><!-- </li> --></ul><div class="share-btn"><i class="icon-forward"></i></div></div></div></div></div><article class="article-content font-normal"><div class="article-header"><header><small></small><h1>癌症新藥，中國製造</h1></header><div class="byline-row"><div class="byline-box"><div class="byline"><address>黃瑞黎</address><time pudate="2018-01-04 09:37:45" datetime="2018-01-04 09:37:45">2018年1月4日</time></div><div class="share-btn"><i class="icon-forward"></i></div></div></div></div><figure class="article-span-photo"><img src="../../../../../static01.nyt.com/images/2018/01/04/business/04CHINAPHARMA5/merlin_131519837_5b70c547-0717-4148-ac1a-e3ac26709e4e-master1050.html" width="1050" height="700" alt="香港和記中國醫療科技有限公司擁有的一家上海化學實驗室正在與阿斯利康合作，開發一種治療肺癌、腎癌、胃癌和結腸癌的藥物。"><figcaption><span>香港和記中國醫療科技有限公司擁有的一家上海化學實驗室正在與阿斯利康合作，開發一種治療肺癌、腎癌、胃癌和結腸癌的藥物。</span> <cite>Yuyang Liu</cite></figcaption></figure><div class="row"><div class="article-left"><section class="article-body"><div class="article-partial"><div class="article-body-item col-lg-5"><div class="article-paragraph">上海——一種新藥有望阻止癌細胞擴散到其他器官；另一種可以治療血癌；還有一種利用人體的免疫系統來殺死腫瘤。</div><div class="article-paragraph">這三種藥都展示出令人鼓舞的效果，只需再過一道關坎就能獲得在美國上市的批准。這些藥還有另一個共同特點：它們都是中國創造的。</div><div class="article-paragraph">多年來，中國的製藥業一直把注意力集中在仿製西藥上。讓新藥獲得批準是一個令人沮喪且耗時的過程。企業認為，將數百萬美元投入藥物研發風險大，不如把精力放在更安全的收入來源上。</div><div class="article-paragraph">現在，中國正努力在全球製藥業發揮更大的作用。中國有數百萬癌症或糖尿病患者，政府已把創新藥物作為國家重點。官員已承諾加快藥品審批速度，為了扭轉人才外流，還在大力吸引科學家回國工作。當局為研發提供土地、撥款、稅收減免以及投資。</div></div><div class="article-body-aside col-lg-3"><div id="subscribe_cont" style="margin: 0 auto;" class="container"></div></div></div><div class="big_ad" id="medium-rectangle-ad-0" data-target="{&quot;pos&quot;:&quot;mid1&quot;,&quot;adv&quot;:&quot;&quot;}"><small>廣告</small></div><div class="article-partial"><div class="article-body-item col-lg-5"><div class="article-paragraph"><div data-poster="jpg" data-mp4="https://int.nyt.com/data/videotape/finished/2018/01/1514829011/30214483a-chinapharma-yuyang-liu-video-15-1024w.mp4" data-webm="https://int.nyt.com/data/videotape/finished/2018/01/1514829011/30214483a-chinapharma-yuyang-liu-video-15-1024w.webm" class="J-vhs-cont"></div></div><div class="article-paragraph">這三種新藥仍需通過美國監管這道難關。如果通過的話，它們將成為中國生產前沿療法的能力越來越強的證明，提高這種能力是中國經濟向高附加值及日益複雜的行業進行更大範圍轉型的一部分。</div><div class="article-paragraph">與更大範圍的工業相比，中國的藥物研發仍處於早期階段。但一些專家說，中國製藥企業與輝瑞(Pfizer)和阿斯利康(AstraZeneca)這些製藥巨頭平起平坐只是時間問題。</div><div class="article-paragraph">「這不是他們做得到、做不到的問題，」醫療投資基金奧博亞洲(OrbiMed Asia)的資深董事總經理王健說。「他們一定能做到。」</div><div class="article-paragraph">直到現在，在中國得到高質量的藥品仍是個問題。許多人從香港和澳門購買藥物，港澳地區受不同的法律管轄；網上有專門討論從印度走私仿製藥的論壇；還有人購買原材料在自己家裡製藥；出得起這筆錢的人<a href="../../../20170531/china-medical-tourism-hospital/index.html">飛到美國去看病</a>。</div><div class="article-paragraph">越來越多的公司正在試圖解決藥品短缺的問題。得到香港首富李嘉誠支持的和黃中國醫藥科技(Hutchison China MediTech)2000年成立時曾嘗試過中草藥的開發。2005年，和黃醫藥開始研發抗癌藥物。</div><div class="article-paragraph">在上海的主要實驗室裡有多達350名科學家，他們被測試室中的嚙齒類動物環繞著。半數以上的科學家正在努力尋找新藥。</div><div class="article-paragraph"><figure class="article-inline-photo large"><div class="img-box"><img src="../../../../../static01.nyt.com/images/2018/01/04/business/04CHINAPHARMA4/merlin_131528813_1e2e4615-21bf-47e6-bd41-4fc222e237c7-master1050.html" alt="上海地方政府官員讓天境製藥的實驗室使用位於一個高科技商業園的空間。" data-src="../../../../../static01.nyt.com/images/2018/01/04/business/04CHINAPHARMA4/merlin_131528813_1e2e4615-21bf-47e6-bd41-4fc222e237c7-master1050.html"></div><figcaption><span>上海地方政府官員讓天境製藥的實驗室使用位於一個高科技商業園的空間。</span> <cite>Yuyang Liu</cite></figcaption></figure></div><div class="article-paragraph">去年10月，和黃醫藥報告說，在二期臨床試驗中，60%以上的患者對公司與阿斯利康共同研發的savolitinib有積極反應。Savolitinib是首種可用於治療肺癌、腎癌、胃癌和結腸直腸癌的藥物，通常與阿斯利康的其他藥物一起使用，把允許癌症擴散的信號傳導通路阻斷掉。</div><div class="article-paragraph"><div data-poster="jpg" data-mp4="https://int.nyt.com/data/videotape/finished/2018/01/1514829011/30214483a-chinapharma-yuyang-liu-video-2-1024w.mp4" data-webm="https://int.nyt.com/data/videotape/finished/2018/01/1514829011/30214483a-chinapharma-yuyang-liu-video-2-1024w.webm" class="J-vhs-cont"></div></div></div><div class="article-body-aside col-lg-3"></div></div><div class="big_ad" id="medium-rectangle-ad-1" data-target="{&quot;pos&quot;:&quot;mid2&quot;,&quot;adv&quot;:&quot;&quot;}"><small>廣告</small></div><div class="article-partial"><div class="article-body-item col-lg-5"><div class="article-paragraph">和黃醫藥正在等待更多的數據。如果進一步試驗有積極的結果，公司將申請美國食品和藥物管理局（簡稱FDA）所謂的突破性療法認定。</div><div class="article-paragraph">公司仍需要做第三期臨床試驗，這是得到FDA全面批准之前的最後一步，但突破性療法認定可縮短這個最後階段的時間。第三期臨床試驗需要在多達幾千名的患者身上檢驗被測試藥物的安全性和有效性，通常是與安慰劑做對照。</div><div class="article-paragraph">伯恩斯坦研究公司(Bernstein Research)亞太醫療行業分析師勞拉·納爾遜·卡尼(Laura Nelson Carney)說，第三期臨床試驗的成功率從行業平均水平來看是60%到70%。</div><div class="article-paragraph">如果一切都按計劃順利進行，監管部門最早可能在2019年底批准，和黃醫藥首席執行官賀雋(Christian Hogg)說。「花了20年的時間，才能突然成功，這就是我們此刻的情況，」他說。</div><div class="article-paragraph">中國上次為全球製藥業開發出新藥是在1970年代。在毛澤東號召中國科學家<a href="http://www.nytimes.com/2012/01/17/health/for-intrigue-malaria-drug-artemisinin-gets-the-prize.html">研發新的治療瘧疾藥物</a>之後，發現青蒿素的功勞歸給了屠呦呦。但是，青蒿素在很多年後才得到全球的認可，那是在瑞士製藥公司諾華(Novartis)在1990年代末購買了中國專利、開始生產該藥之後。屠呦呦最終<a href="#https://cn.nytimes.com/china/20151008/c08tuyouyou/">在2015年獲得了諾貝爾獎</a>。</div><div class="article-paragraph">這一切都在改變。除了和黃醫藥，另一家名為百濟神州(BeiGene)的公司已在對兩種藥物在全球進行第三期臨床試驗，一種是用於治療一種最常見的血癌、淋巴瘤的藥物，另一種是以消滅腫瘤為目的的免疫治療藥物。百濟神州還在與賽爾基因(Celgene)和默克公司(Merck)合作開發抗癌藥物。</div></div><div class="article-body-aside col-lg-3"></div></div><div class="big_ad" id="medium-rectangle-ad-2" data-target="{&quot;pos&quot;:&quot;mid3&quot;,&quot;adv&quot;:&quot;&quot;}"><small>廣告</small></div><div class="article-partial"><div class="article-body-item col-lg-5"><div class="article-paragraph">卡尼說，她預計在未來五年內，將有20或30個中國製造的藥物在美國申請進行第三期臨床試驗。美國是世界上最大的抗癌藥物市場。她說，從中國目前的定價模式來看，那些試驗成功、獲得批准的藥物很可能會比外國公司生產的藥物價格更低。</div><div class="article-paragraph">與此同時，大型製藥企業正在克服它們對中國猖獗的偽造以及繁瑣的官僚手續長久以來的擔心，紛紛在中國建立自己的實驗室。強生(Johnson & Johnson)、諾華和賽諾菲(Sanofi)都已經在上海成立了為中國患者製藥的研究中心。高管表示，中國政府已經在加強保護製藥專利方面取得了進展。</div><div class="article-paragraph"><figure class="article-inline-photo large"><div class="img-box"><img src="../../../../../static01.nyt.com/images/2018/01/04/business/04CHINAPHARMA2/04CHINAPHARMA2-master1050.html" alt="在天境生物領導研究與發展的瓊·沈（音）曾經在美國禮來製藥和輝瑞製藥公司工作了20年。" data-src="../../../../../static01.nyt.com/images/2018/01/04/business/04CHINAPHARMA2/04CHINAPHARMA2-master1050.html"></div><figcaption><span>在天境生物領導研究與發展的瓊·沈（音）曾經在美國禮來製藥和輝瑞製藥公司工作了20年。</span> <cite>Yuyang Liu</cite></figcaption></figure></div><div class="article-paragraph">批准的步伐也已加快。在最糟糕的情況下，製藥公司需要等兩年，才獲得開啟臨床試驗的批准，臨床試驗本身需要幾年的時間。在美國，獲得臨床試驗批准的等待期通常是30天。</div><div class="article-paragraph">2015年，畢井泉被任命為中國食品藥品監督管理局局長，在他的領導下，中國藥監局已經開始打擊生產低質量藥物的公司，並同意接受國外的臨床試驗數據。</div><div class="article-paragraph">由於發生了這些轉變，加上政府提供的激勵措施，現在，在海外受過訓練的科學家正在回國工作。</div><div class="article-paragraph">2011年，在美國的禮來公司(Eli Lilly)和輝瑞公司工作了20年之後，申華瓊(Joan Shen)回到上海，領導輝瑞的臨床試驗部門。她現在負責中國生物技術公司泰康生物(I-Mab Biopharma)的研發工作。當地政府幫助這家公司獲得了資金，並在一個高技術園區為公司提供了實驗室空間。</div></div><div class="article-body-aside col-lg-3"></div></div><div class="big_ad" id="medium-rectangle-ad-3" data-target="{&quot;pos&quot;:&quot;mid4&quot;,&quot;adv&quot;:&quot;&quot;}"><small>廣告</small></div><div class="article-partial"><div class="article-body-item col-lg-5"><div class="article-paragraph">申華瓊在比較中美兩國的投資環境時說，「這裡是錢來找我們，而不是需要我們花大量時間去說服投資者。」</div><div class="article-paragraph">儘管前景樂觀，但想要走出國內的中國製藥公司仍面臨著障礙。在美國這樣的主要市場，製藥公司之間的競爭十分激烈，中國企業尤其受到缺少研究資金的妨礙。</div><div class="article-paragraph"><div data-poster="jpg" data-mp4="https://int.nyt.com/data/videotape/finished/2018/01/1514829011/chinapharma2-2-1024w.mp4" data-webm="https://int.nyt.com/data/videotape/finished/2018/01/1514829011/chinapharma2-2-1024w.webm" class="J-vhs-cont"></div></div><div class="article-paragraph">中國公司江蘇恆瑞醫藥目前正在從生產仿製藥向開發新藥轉型，這家公司的研究預算是所有中國製藥公司中最大的。但與輝瑞2016年花費的78億美元的年度研究支出相比，江蘇恆瑞1.8億美元的年度研究支出相形見絀。</div><div class="article-paragraph">儘管如此，恆瑞醫藥已有幾種進入早期試驗的藥物。用研發主管張連山的話說，公司的「最終目標」是獲得美國監管部門的批准。</div><div class="article-paragraph">張連山說，「如果你有一個得到美國FDA批准的藥物，那才是創新的真正表現。」</div></div><div class="article-body-aside col-lg-3"></div></div></section><footer class="author-info"><p>黃瑞黎(Sui-Lee Wee)是《紐約時報》駐京記者。</p><p>歡迎在Twitter上關注本文作者黃瑞黎 <a rel="nofollow" target="_blank" href="https://www.twitter.com/suilee">@suilee</a>。</p><p>Zhang Tiantian對本文有研究貢獻。</p><p>翻譯：Cindy Hao</p><p><a rel="nofollow" target="_blank" href="http://www.nytimes.com/2018/01/03/business/china-drugs-health-care.html">點擊查看本文英文版。</a></p></footer></div></div></article><div class="container article-footer"><div class="row"><div class="col-lg-12 mobile-refer-cont" id="J_hideRefer"><div class="related-cont"><h4>相關報導</h4><ul class="refer-list"><li class="article-refer"><div class="refer-list-item"><a href="../../../20170531/china-medical-tourism-hospital/zh-hant/index.html" title="中國富人出國求醫，順便受教育"><div><h3 class="refer-list-headline">中國富人出國求醫，順便受教育</h3><p class="refer-pubdate">2017年5月31日</p></div><img alt="中國富人出國求醫，順便受教育" src="../../../../../static01.nyt.com/images/2017/03/28/business/00CHINAMEDICAL2/00CHINAMEDICAL2-thumbLarge.html" width="75" height="75"></a></div></li><li class="article-refer"><div class="refer-list-item"><a href="#https://cn.nytimes.com/china/20151008/c08tuyouyou/zh-hant/" title="屠呦呦、諾貝爾獎和毛主席的號召"><div><h3 class="refer-list-headline">屠呦呦、諾貝爾獎和毛主席的號召</h3><p class="refer-pubdate">2015年10月8日</p></div><img alt="屠呦呦、諾貝爾獎和毛主席的號召" src="../../../../../static01.nyt.com/images/2015/10/06/science/07tuyouyou-web1/07tuyouyou-web1-thumbLarge.html" width="75" height="75"></a></div></li></ul></div></div><div class="col-lg-12"><div class="related hot_article"><h5 class="related-title">最受歡迎</h5><ol class="related-articles"><li><a href="#https://cn.nytimes.com/opinion/20220127/pakistan-united-states-china/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>「巴鐵」軍方為什麼想與中國保持距離？</h4><img alt="「巴鐵」軍方為什麼想與中國保持距離？" src="../../../../../static01.nyt.com/images/2022/01/24/opinion/21Rafiq1/21Rafiq1-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/usa/20220127/computer-chip-shortage-taiwan/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>戰棋推演報告稱台灣半導體工廠停產可能引發中美衝突</h4><img alt="戰棋推演報告稱台灣半導體工廠停產可能引發中美衝突" src="../../../../../static01.nyt.com/images/2022/01/26/us/politics/26dc-wargames/merlin_177315390_5fcf8532-e370-4f81-8f99-45c6c83044f4-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/opinion/20220126/china-covid-19/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>中國追求「清零」將把國家置於災難之中</h4><img alt="中國追求「清零」將把國家置於災難之中" src="../../../../../static01.nyt.com/images/2022/01/25/opinion/25emanuel/25emanuel-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/sports/20220127/peng-shuai-china-australian-open/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>澳網再現「彭帥在哪裡」：球員和觀賽者拒絕遺忘、為其發聲</h4><img alt="澳網再現「彭帥在哪裡」：球員和觀賽者拒絕遺忘、為其發聲" src="../../../../../static01.nyt.com/images/2022/01/26/sports/26aus-china1/merlin_199503951_9c695f25-2b8e-41b4-9c97-bf91de7aa190-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/usa/20220125/gang-chen-mit-china/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>「我們在殘害我們自己」：華裔教授陳剛案背後的憤怒與幻滅</h4><img alt="「我們在殘害我們自己」：華裔教授陳剛案背後的憤怒與幻滅" src="../../../../../static01.nyt.com/images/2022/01/24/science/24CHEN-promo/24CHEN-promo-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/opinion/20220127/virtual-reality-simulation/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>你可以開始相信，我們有可能會活在虛擬現實裡</h4><img alt="你可以開始相信，我們有可能會活在虛擬現實裡" src="../../../../../static01.nyt.com/images/2022/01/26/opinion/26manjoo-image/26manjoo-image-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/china/20220124/winter-olympics-china-beijing-xi-jinping/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>不再取悅世界：一屆展現習近平全面願景的冬奧會</h4><img alt="不再取悅世界：一屆展現習近平全面願景的冬奧會" src="../../../../../static01.nyt.com/images/2022/01/13/world/00xi-olympics-30/00xi-olympics-30-thumbLarge.jpg"></article></a></li><li><a href="../../../20220126/imf-world-economic-report/zh-hant/indexf61c.html?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>國際貨幣基金組織稱中美經濟放緩將拖累全球經濟</h4><img alt="國際貨幣基金組織稱中美經濟放緩將拖累全球經濟" src="../../../../../static01.nyt.com/images/2022/01/25/multimedia/25global-econ-brf/25global-econ-brf-thumbLarge-v2.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/asia-pacific/20220126/north-korea-launches-missiles-kim/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>朝鮮突然頻繁試射導彈傳遞了什麼信息？</h4><img alt="朝鮮突然頻繁試射導彈傳遞了什麼信息？" src="../../../../../static01.nyt.com/images/2022/01/21/world/00nkorea-gameplan-01/00nkorea-gameplan-01-thumbLarge.html"></article></a></li><li><a href="#https://cn.nytimes.com/china/20220124/china-zero-covid-policy/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>多地封鎖引發沮喪與抱怨，中國「清零」政策還能走多遠？</h4><img alt="多地封鎖引發沮喪與抱怨，中國「清零」政策還能走多遠？" src="../../../../../static01.nyt.com/images/2022/01/20/world/00virus-china-lockdown-01/00virus-china-lockdown-01-thumbLarge.html"></article></a></li></ol></div></div></div></div></div><footer class="row copy-footer">&copy; 2022 The World Economy Observer.<ul class="footerLinkList"><li class="footerLink"><a rel="nofollow" href="/ad/">广告</a></li><li class="footerLink"><a rel="nofollow" href="/about-us/">关于我们</a></li><li class="footerLink"><a rel="nofollow" href="/contact/">联系我们</a></li><li class="footerLink"><a rel="nofollow" href="/tos/">服务条款</a></li><li class="purr-content"></li></ul></footer><script src="/d1f1eryiqyjs0r.cloudfront.net/js/libs/require619b.js?v=f1810d8"></script><script src="/d1f1eryiqyjs0r.cloudfront.net/js/web/article.min619b.js?v=f1810d8"></script></main></body>
<!-- Mirrored from cn.nytimes.com/business/20180104/china-drugs-health-care/zh-hant/ by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 28 Jan 2022 14:13:01 GMT -->
</html>